neoadjuvant therapy是在肿瘤手术之前进行的治疗。与adjuvant therapy不同,neoadjuvant therapy的主要目的是在手术前使肿瘤缩小或完全消失,以便更容易进行手术切除。这种治疗方法通常包括药物治疗(如化疗、靶向治疗)或放疗,也可以同时使用多种治疗手段。 neoadjuvant therapy的优势在于可以降低肿瘤的体积,减少手术的复杂性和困难...
Treating bladder cancer: Neoadjuvant vs adjuvant therapyM.D. MichaelsonOncology
Neoadjuvant or adjuvant chemotherapy is commonly administered for patients with muscle-invasive bladder cancer, since the disease is commonly diagnosed with distant metastases. In many circumstances, neoadjuvant therapy is preferred, since individuals often tolerate chemotherapy better when it is administered ...
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004;2:35.Malthaner RA, Wong RK, Rumble RB, Zuraw L (2004) Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta- analysis. BMC Med 2: 35...
One of the topics that they dealt with is one that's near and dear to my heart, which is the use of neoadjuvant therapy. You've heard me speak on this before, but it seems that the huge discussion today is still adjuvant vs neoadjuvant. I want to clarify a few items here and also...
The second arm of the trial received placebo plus chemotherapy as neoadjuvant therapy prior to surgery, followed by placebo as adjuvant therapy post surgery. At the first interim analysis, investigators announced that 1 of the dual primary end points, event-free survival (EFS), was met, as ...
Zhang, S.Q., Villaflor, V.M. (2014). Esophageal Cancer: Neoadjuvant and Adjuvant Therapy. In: Fisichella, P., Allaix, M., Morino, M., Patti, M. (eds) Esophageal Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-04337-1_17 ...
Overall, the evidence does not support the use of neoadjuvant or adjuvant therapy for patients with resectable cancer of the lower two-thirds of the esophagus. Surgical resection alone should remain the standard for localized thoracic esophageal cancer. Patient staging information can be found in ...
Adjuvant therapy (AT) and neoadjuvant therapy (NAT) are standard treatments for pancreatic ductal adenocarcinoma (PDAC) depending on the status of the disease. However, whether AT improves survival after NAT and radical resection in all TNM stages remains unclear. ...
Massimo Di Maio, MD JAMA Network Open Key Points Question Is administration of programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors both before and after surgery (neoadjuvant-adjuvant treatment) associated with better outcomes than administration of the thera...